Aichi cancer center central hospital

Nagoya, Aichi-ken 464-8681

0 studies enrolling now · 9 studies all time

What they study most

Advanced Malignancies Except Leukemia, Carcinoma, Non-Small-Cell Lung, Metastatic Colorectal Cancer, Non Squamous Lung Cancer, Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer ALK-positive, Non-Small Cell Lung Cancer ROS Marker Positive, Non-Small Cell Lung Cancer c-Met Dependent, Squamous Cell Carcinoma of the Head and Neck, Squamous Cell Carcinoma of the Head and Neck (SCCHN), Systemic Anaplastic Large-Cell Lymphoma

Studies at this site

• A Study Of Lorlatinib Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLC — Running, not enrolling
• Safety And Efficacy Study Of Palbociclib Plus Cetuximab Versus Cetuximab To Treat Head And Neck Cancer — Completed
• Study to Evaluate Safety, Efficacy, Pharmacokinetics And Pharmacodynamics Of Avelumab In Combination With Either Crizotinib Or PF-06463922 In Patients With NSCLC. (Javelin Lung 101) — Stopped early
• A Study Of Oral PF-02341066, A C-Met/Hepatocyte Growth Factor Tyrosine Kinase Inhibitor, In Patients With Advanced Cancer — Completed
• Study To Compare Avelumab In Combination With Standard of Care Chemoradiotherapy (SoC CRT) Versus SoC CRT for Definitive Treatment In Patients With Locally Advanced Squamous Cell Carcinoma Of The Head And Neck (JAVELIN HEAD AND NECK 100) — Stopped early
• A Study Of PF-05212384 Plus Irinotecan Vs Cetuximab Plus Irinotecan In Patients With KRAS And NRAS Wild Type Metastatic Colorectal Cancer — Stopped early
• A Clinical Trial Testing The Efficacy Of Crizotinib Versus Standard Chemotherapy Pemetrexed Plus Cisplatin Or Carboplatin In Patients With ALK Positive Non Squamous Cancer Of The Lung — Completed
• An Investigational Drug, PF-02341066, Is Being Studied In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene — Completed
• An Investigational Drug, PF-02341066 Is Being Studied Versus Standard Of Care In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene — Completed